From Carcinosarcoma to Circulating Tumor DNA: The Importance of Investigator-Initiated Research in Endometrial Cancer
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
From Carcinosarcoma to Circulating Tumor DNA: The Importance of Investigator-Initiated Research in Endometrial Cancer
-
ナレーター：
-
著者：
Drs Ursula A. Matulonis and Stephanie Lheureux discuss the importance of investigator-initiated clinical trials in endometrial cancer, research on carcinosarcoma, and ctDNA.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep4-2026a10006ie. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview
Advances in Antibody-Drug Conjugates for Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/40111079/
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/
Translational Randomized Phase II Trial of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent, or Metastatic Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35288469/
Elucidating Divergent Biology in Uterine Carcinosarcoma https://pubmed.ncbi.nlm.nih.gov/40850250/
The Immune Microenvironment in Endometrial Carcinoma: Mechanisms and Therapeutic Targeting https://pubmed.ncbi.nlm.nih.gov/40746533/
Epithelial-Mesenchymal Transition Orchestrates Tumor Microenvironment: Current Perceptions and Challenges https://pubmed.ncbi.nlm.nih.gov/40176117/
Comparative Modeling of Recent and Projected Trends in the Incidence and Mortality of Uterine Cancer https://pubmed.ncbi.nlm.nih.gov/41643197/
Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39417689/
Targeting CDK2 for Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/40802510/
PYNNACLE Phase II Trial Assessing Rezatapopt (PC14586), a Selective p53 Reactivator, in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation https://www.gynecologiconcology-online.net/article/S0090-8258%2825%2900347-6/abstract
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.